Kiromic BioPharma, Inc. (KRBPQ)
OTCMKTS · Delayed Price · Currency is USD
0.0001
0.00 (0.00%)
Jul 30, 2025, 9:33 AM EST
Kiromic BioPharma Balance Sheet
Financials in millions USD. Fiscal year is January - December.
Millions USD. Fiscal year is Jan - Dec.
Assets
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Cash & Equivalents | 1.14 | 3.2 | 0.65 | 25.35 | 10.15 |
Cash & Short-Term Investments | 1.14 | 3.2 | 0.65 | 25.35 | 10.15 |
Cash Growth | -64.51% | 396.59% | -97.45% | 149.78% | 426.18% |
Other Receivables | - | - | - | 0.02 | - |
Receivables | - | - | - | 0.02 | - |
Prepaid Expenses | 1.51 | 1.23 | 1.04 | 1.7 | 0.59 |
Restricted Cash | 0.66 | - | - | - | - |
Total Current Assets | 3.3 | 4.43 | 1.69 | 27.07 | 10.74 |
Property, Plant & Equipment | 5.22 | 7.72 | 10.25 | 3.63 | 2.07 |
Other Long-Term Assets | 0.02 | 0.02 | 0.02 | 0.03 | 0.02 |
Total Assets | 8.55 | 12.17 | 11.97 | 30.73 | 12.83 |
Liabilities
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Accounts Payable | 2.68 | 2.14 | 7.31 | 2.21 | 0.67 |
Accrued Expenses | 3.89 | 3.16 | 1.02 | 0.74 | 0.33 |
Short-Term Debt | 13.66 | 14 | 4.37 | 0.45 | 0.47 |
Current Portion of Leases | 0.69 | 0.63 | 0.58 | - | - |
Other Current Liabilities | - | 0.45 | - | - | - |
Total Current Liabilities | 20.9 | 20.38 | 13.28 | 3.41 | 1.47 |
Long-Term Debt | - | - | 2.91 | - | - |
Long-Term Leases | 0.23 | 0.91 | 1.54 | - | - |
Total Liabilities | 21.13 | 21.29 | 17.74 | 3.41 | 1.47 |
Shareholders' Equity
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Common Stock | 0 | 0 | 0 | 0 | 0 |
Additional Paid-In Capital | 137.21 | 113.78 | 96.17 | 94.54 | 52.99 |
Retained Earnings | -149.8 | -122.9 | -101.95 | -67.22 | -41.63 |
Total Common Equity | -12.59 | -9.12 | -5.77 | 27.32 | 11.36 |
Shareholders' Equity | -12.59 | -9.12 | -5.77 | 27.32 | 11.36 |
Total Liabilities & Equity | 8.55 | 12.17 | 11.97 | 30.73 | 12.83 |
Additional Metrics
Fiscal Year | FY 2024 | FY 2023 | FY 2022 | FY 2021 | FY 2020 |
|---|---|---|---|---|---|
Period Ending | Dec '24 Dec 31, 2024 | Dec '23 Dec 31, 2023 | Dec '22 Dec 31, 2022 | Dec '21 Dec 31, 2021 | Dec '20 Dec 31, 2020 |
Total Debt | 14.57 | 15.54 | 9.41 | 0.45 | 0.47 |
Net Cash (Debt) | -13.43 | -12.34 | -8.77 | 24.9 | 9.68 |
Net Cash Growth | - | - | - | 157.16% | 401.92% |
Net Cash Per Share | -9.19 | -11.24 | -16.10 | 65.43 | 64.47 |
Filing Date Shares Outstanding | 1.53 | 1.29 | 0.98 | 0.52 | 0.24 |
Total Common Shares Outstanding | 1.53 | 1.26 | 0.65 | 0.52 | 0.24 |
Working Capital | -17.6 | -15.95 | -11.59 | 23.66 | 9.27 |
Book Value Per Share | -8.21 | -7.25 | -8.91 | 52.92 | 46.48 |
Tangible Book Value | -12.59 | -9.12 | -5.77 | 27.32 | 11.36 |
Tangible Book Value Per Share | -8.21 | -7.25 | -8.91 | 52.92 | 46.48 |
Machinery | 3.47 | 3.26 | 3.18 | 1.61 | 0.8 |
Construction In Progress | 0.02 | 0.1 | - | 1.23 | 0.45 |
Leasehold Improvements | 7.37 | 7.37 | 7.3 | 1.46 | 1.23 |